Yonsei Med J.  2007 Dec;48(6):1072-1074. 10.3349/ymj.2007.48.6.1072.

Value of Manganese-Enhanced T1- and T2-Weighted MR Cholangiography for Differentiating Cystic Parenchymal Lesions from Cystic Abnormalities which Communicate with Bile Ducts

• Park MS
• Yu JS
• Lee JH
• Kim KW

• KMID: 1786229
• DOI: http://doi.org/10.3349/ymj.2007.48.6.1072

Abstract

We present a case report to show how manganese-enhanced T1- and T2-weighted MR cholangiography could differentiate cystic parenchymal lesions from cystic abnormalities which communicate with the bile ducts.

Keyword

Bile ducts; MR; MR contrast

MeSH Terms

Bile Ducts/*pathology
Cholangiopancreatography, Magnetic Resonance/*methods
Choledochal Cyst/diagnosis
Contrast Media/chemistry
Cysts/diagnosis
Diagnosis, Differential
Humans
Liver/*pathology
Male
Manganese/*chemistry
Middle Aged
Reproducibility of Results
Sensitivity and Specificity

Figure

• 

  Fig. 1 A 53-year-old-man with multiple biliary hamartomas. (A) Contrast-enhanced CT shows multiple, nonenhancing, small, hypodense nodules scattered throughout his entire liver. (B) Hepatic US shows an inhomogeneous echo texture with some hypoechoic (white arrow) and hyperechoic (black arrow) nodules. We could not differentiate cystic lesions from solid nodules on CT and sonographic findings. (C) Coronal pre-mangafodipir half-Fourier RARE MR cholangiographic image shows multiple, small, and well-defined high signal intensity lesions scattered throughout the liver. The bile ducts appeared as high signal intensity structures (arrow). The relationship between the bile ducts and the multiple small high signal intensity lesions could not be clarified in this study. (D) Coronal MIP from post-mangafodipir 3D fat-suppressed T1-weighted gradient echo image shows only bile ducts (arrow) as high signal intensity structures. (E) As in (A), following mangafodipir administration. There is loss of bile duct signals, but signal persists in the multiple small cystic lesions.

Reference

1. Mitchell DG, Alam F. Mangafodipir trisodium: effects on T2- and T1-weighted MR cholangiography. J Magn Reson Imaging. 1999. 9:366–368.

2. Lee VS, Rofsky NM, Morgan GR, Teperman LW, Krinsky GA, Berman P, et al. Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy. AJR Am J Roentgenol. 2001. 176:906–908.

3. Vitellas KM, El-Dieb A, Vaswani KK, Bennett WF, Fromkes J, Ellison C, et al. Using contrast-enhanced MR cholangiography with IV mangafodipir trisodium (Teslascan) to evaluate bile duct leaks after cholecystectomy: a prospective study of 11 patients. AJR Am J Roentgenol. 2002. 179:409–416.

4. Kim KW, Park MS, Yu JS, Chung JP, Ryu YH, Lee SI, et al. Acute cholecystitis at T2-weighted and manganese enhanced T1-weighted MR cholangiography: preliminary study. Radiology. 2003. 227:580–584.

5. Dong Q, Jiang B, Zhang H, Jiang Z, Lu H, Yang C, et al. Management strategy for congenital choledochal cyst with co-existing intrahepatic dilation and aberrant bile duct as well as other complicated biliary anomalies. Yonsei Med J. 2006. 47:826–832.

6. Bang S, Suh JH, Park BK, Park SW, Song SY, Chung JB. The relationship of anatomic variation of pancreatic ductal system and pancreaticobiliary diseases. Yonsei Med J. 2006. 47:243–248.

7. Mortelé B, Mortelé K, Seynaeve P, Vandevelde D, Kunnen M, Ros PR. Hepatic bile duct hamartomas (von Meyenburg Complexes): MR and MR cholangiography findings. J Comput Assist Tomogr. 2002. 26:438–443.